Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled

NCT06961370 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT06961370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06961370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Terminated
Start date
July 16, 2025
Completion date
March 3, 2026
Enrollment
27 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, geographic atrophy